Stock Analysis

February 2025's Top Dividend Stocks For Income Growth

Published

As the global markets navigate a complex landscape marked by volatile tech stocks, geopolitical tariff tensions, and shifting monetary policies, investors are seeking stability and growth opportunities. In this environment, dividend stocks can offer a reliable income stream while potentially benefiting from economic recovery trends and positive corporate earnings surprises.

Top 10 Dividend Stocks

NameDividend YieldDividend Rating
Totech (TSE:9960)3.84%★★★★★★
Tsubakimoto Chain (TSE:6371)4.33%★★★★★★
Wuliangye YibinLtd (SZSE:000858)4.05%★★★★★★
Daito Trust ConstructionLtd (TSE:1878)4.01%★★★★★★
GakkyushaLtd (TSE:9769)4.46%★★★★★★
China South Publishing & Media Group (SHSE:601098)4.01%★★★★★★
Guangxi LiuYao Group (SHSE:603368)3.41%★★★★★★
HUAYU Automotive Systems (SHSE:600741)4.46%★★★★★★
Nihon Parkerizing (TSE:4095)3.95%★★★★★★
FALCO HOLDINGS (TSE:4671)6.70%★★★★★★

Click here to see the full list of 1961 stocks from our Top Dividend Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Novartis (SWX:NOVN)

Simply Wall St Dividend Rating: ★★★★★☆

Overview: Novartis AG is involved in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines globally and has a market cap of CHF189.79 billion.

Operations: Novartis generates revenue primarily from its Innovative Medicines segment, which accounts for $51.72 billion.

Dividend Yield: 3.6%

Novartis has announced a proposed dividend increase to CHF 3.50 per share for 2024, marking its 28th consecutive annual rise. The company's dividends are well-covered by earnings and cash flows, with payout ratios of 65.3% and 54.6%, respectively, indicating sustainability. Despite its dividend yield being lower than the top Swiss market payers, Novartis maintains stable and reliable payments over the past decade, supported by consistent revenue growth and strategic initiatives in healthcare innovation.

SWX:NOVN Dividend History as at Feb 2025

Allmind Holdings (TPEX:2718)

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Allmind Holdings Corporation is involved in the development and rental of houses and buildings in Taiwan, with a market cap of NT$6.33 billion.

Operations: Allmind Holdings Corporation generates revenue from Operating Construction amounting to NT$4.67 billion.

Dividend Yield: 4.1%

Allmind Holdings reported a substantial earnings increase, with TWD 3,751.47 million in sales for Q3 2024. Despite the impressive growth and low payout ratio of 8.6%, its dividend yield of 4.15% is below the top quartile in Taiwan. The dividend history is marked by volatility, lacking reliability over the past decade, though dividends are well-covered by earnings and cash flows. Recent expansion plans include acquiring land for new office construction in Kaohsiung.

TPEX:2718 Dividend History as at Feb 2025

Compucase Enterprise (TWSE:3032)

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Compucase Enterprise Co., Ltd. designs and manufactures PC cases, power supplies, rackmount chassis, and cabinets globally with a market cap of NT$9.31 billion.

Operations: Compucase Enterprise Co., Ltd. generates revenue from several segments, including Channel (NT$449.15 million), Manufacturing (NT$4.22 billion), Server Casing Segment (NT$4.63 billion), Operation Headquarters (NT$5.88 billion), and Medical Equipment Segment (NT$479.87 million).

Dividend Yield: 4.2%

Compucase Enterprise's dividend yield of 4.22% is below the top quartile in Taiwan, with a payout ratio of 68.2%, indicating dividends are covered by earnings and cash flows at 30.2%. However, its dividend history over the past decade has been unreliable and volatile despite some growth. Recent financial performance shows a decline in revenue, with December 2024 net revenue down to TWD 650.96 million, reflecting a challenging environment for sustaining dividends amidst fluctuating earnings.

TWSE:3032 Dividend History as at Feb 2025

Key Takeaways

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Novartis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com